Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 64Breast Neoplasms 20Kidney Neoplasms 19Gastrointestinal Stromal Tumors 16Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Colorectal Neoplasms 6Neuroendocrine Tumors 5Carcinoma, Hepatocellular 5Carcinoma 5Thyroid Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Kidney Diseases 3Glioblastoma 3Esophageal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Astrocytoma 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3

Interventions

Bevacizumab 3Lapatinib 2vistusertib 1brolucizumab 1aflibercept 1Vascular Endothelial Growth Factor A 1Sunitinib 1HDAC-42 1Everolimus 1Crizotinib 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibromatosis 2 × Sunitinib × Clear all
NCT00589784 2016-01-25

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
50 enrolled 6 charts
CNS

Brain Neoplasms, Meningioma, Neurofibromatosis 1, Neurofibromatosis 2, Central Nervous System Neoplasms, Neurofibromatoses, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡